[Clinical experiments with a new derivative of 6-aminopenicillanic acid: hetacillin potassium].
D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004357:Drug Synergism; D004361:Drug Tolerance; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007223:Infant; D007273:Injections, Intramuscular; D008012:Lidocaine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D008875:Middle Aged; D010406:Penicillins / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy; D013844:Thiazoles / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D007093:Imidazoles; D010406:Penicillins; D013844:Thiazoles; D000667:Ampicillin; D008012:Lidocaine
Esperienze cliniche con un nuovo derivato dell'acido 6-aminopenicillanico: etacillina potassica.